Table 1.

Analysis of overall survival in TCGA patients with LIHC by univariate and multivariate methods.

Characteristics	Total (N)	Univariate Analysis		Multivariate Analysis
		Hazard Ratio (95% CI)	p Value	Hazard Ratio (95% CI)	p Value
Age	373
≤60	177	Reference
>60	196	1.205 (0.850–1.708)	0.295
Gender	373
Female	121	Reference
Male	252	0.793 (0.557–1.130)	0.2
Race	361
White	185	Reference
Asian and Black or African American	176	0.791 (0.551–1.135)	0.203
BMI	336
≤25	177	Reference
>25	159	0.798 (0.550–1.158)	0.235
Tumor status	354
Tumor free	202	Reference
With tumor	152	2.317 (1.590–3.376)	<0.001	1.794 (1.200–2.684)	0.004
Residual tumor	344
R0	326	Reference
R1 and R2	18	1.604 (0.812–3.169)	0.174
Pathologic stage	349
Stage I and Stage II	259	Reference
Stage III and Stage IV	90	2.504 (1.727–3.631)	<0.001	2.075 (1.393–3.091)	<0.001
Adjacent hepatic tissue inflammation	236
None	118	Reference
Mild and Severe	118	1.194 (0.734–1.942)	0.475
AFP (ng/mL)	279
≤400	215	Reference
>400	64	1.075 (0.658–1.759)	0.772
Albumin (g/dL)	299
<3.5	69	Reference
≥3.5	230	0.897 (0.549–1.464)	0.662
Prothrombin time	296
≤4	207	Reference
>4	89	1.335 (0.881–2.023)	0.174
Vascular invasion	317
No	208	Reference
Yes	109	1.344 (0.887–2.035)	0.163
RECQL (high vs. low)	373	1.454 (1.026–2.060)	0.035	1.047 (0.637–1.719)	0.858
BLM (high vs. low)	373	1.270 (0.900–1.793)	0.174
WRN (high vs. low)	373	1.473 (1.041–2.086)	0.029	1.235 (0.752–2.027)	0.405
RECQL4 (high vs. low)	373	1.672 (1.180–2.371)	0.004	1.554 (1.042–2.318)	0.031
RECQL5 (high vs. low)	373	1.554 (1.098–2.199)	0.013	1.221 (0.825–1.809)	0.318